Amicus Therapeutics) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases.
Location: United States, Pennsylvania, Philadelphia
Employees: 501-1000
Founded date: 2002
Investors 4
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
| - | Prospect V... | prospectve... |
| - | Frazier Li... | frazierls.... |
| - | Canaan Par... | canaan.com |
Mentions in press and media 24
| Date | Title | Description | Source |
| 14.03.2024 | Rare Disease Advocates Learn to Accelerate Therapeutic Devel... | RARE Drug Development Symposium The RARE Drug Development Symposium, hosted by Global Genes and the ... | prweb.com/... |
| 05.12.2023 | Carmot’s chance of beating the odds in the biotech market ju... | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech ne... | statnews.c... |
| 02.03.2022 | Alliance for Artificial Intelligence in Healthcare Elects Ne... | “AI will continue to have a demonstrable impact on human health. Having spent the last three years i... | prweb.com/... |
| 22.02.2022 | Tenth Annual Lake Nona Impact Forum Convenes Health And Well... | Deepak Chopra speaks during the Lake Nona Impact Forum “There’s no doubt we live in a different worl... | prweb.com/... |
| 10.01.2022 | Amicus Therapeutics : Reports Preliminary 2021 Revenue and P... | Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue... | marketscre... |
| 22.11.2021 | Amicus Therapeutics : Long-term efficacy with migalastat in ... | Long-term multisystemic efficacy with migalastat in ERT-naïve and ERT-experienced patients with amen... | marketscre... |
| 09.11.2021 | Amicus Therapeutics Announces Third Quarter 2021 Financial R... | Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates 3Q21 Total ... | marketscre... |
| 09.11.2021 | Amicus Therapeutics Announces Third Quarter 2021 Financial R... | 3Q21 Total Galafold® Revenue of $79.5M – an 18% increase over 3Q20 Reiterating 2021 Revenue Guidance... | marketscre... |
| 16.09.2021 | Poster: Cipaglucosidase alfa/miglustat versus alglucosidase ... | EP.196 Cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease:... | marketscre... |
| 05.08.2021 | Amicus Therapeutics : Announces Second Quarter 2021 Financia... | 2Q21 Total Galafold® (migalastat) Revenue of $77.4M, a 24% increase over 2Q20 On-Track to Achieve Re... | marketscre... |
Show more